| Trial ID: | L2630 |
| Source ID: | NCT05422092
|
| Associated Drug: |
Canagliflozin
|
| Title: |
Canagliflozin on Liver Inflammation Damage in Type 2 Diabetes Patients With Nonalcoholic Fatty Liver Disease
|
| Acronym: |
|
| Status: |
UNKNOWN
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes Mellitus With Complication
|
| Interventions: |
DRUG: Canagliflozin|DRUG: Pioglitazone
|
| Outcome Measures: |
Primary: Plasma cholesteryl ester transfer protein(CETP) concentration in ug/mL, Measurements of liver inflammation and damage, 24 weeks after the date of enrollment|The activity of CEPT in pmol/mL/min, Measurements of liver inflammation and damage, 24 weeks after the date of enrollment | Secondary: Plasma cholesteryl ester transfer protein(CETP) concentration in ug/mL, Measurements of liver inflammation and damage, Baseline|The activity of CEPT in pmol/mL/min, Measurements of liver inflammation and damage, Baseline
|
| Sponsor/Collaborators: |
Sponsor: First Affiliated Hospital Xi'an Jiaotong University
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
80
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC
|
| Start Date: |
2022-09-20
|
| Completion Date: |
2023-12
|
| Results First Posted: |
|
| Last Update Posted: |
2022-09-21
|
| Locations: |
|
| URL: |
https://clinicaltrials.gov/show/NCT05422092
|
